Author: Ashley Myers
-
Clinical Trials and the Advantage of a Feasibility Assessment
In the Spring of 2019, the Emory University Office of the Senior Vice President for Research contracted with Huron Consulting Group to produce an analysis that examined business processes across the life cycle of a grant. The subsequent results of the analysis reported: “Clinical trials are not consistently required to go through a formal feasibility…
-
Important IRB Updates
We have updated Data and Safety Monitoring guidance for Investigator-Initiated studies that are more than minimal risk. It is posted here under “DSMP, Site Monitoring, and DSMB Guidance,” under “Related Guidance.” Please note that some high-complexity studies do require external/independent monitoring, so please consult with the IRB, and/or Margaret Huber in the Office of Research…
-
Valuable Research IT Tools Become Available to All Labs
When Dr. Bruner, Senior Vice President of Research, commissioned the Research IT Task Force in 2019, one of the group’s recommendations was to lower the cost barrier of IT solutions. As a result, we are excited to announce enterprise availability for the REDCap and OpenSpecimen platforms. All research teams will soon be able to utilize…
-
Award Closeout Policy Update
On September 1, 2021, we launched four new/updated policies related to award close outs. These polices were developed in collaboration with RAS leaders, CBOs, and ORA leaders. They were designed to ensure sponsored awards are closed out promptly in COMPASS. This will benefit our research community by streamlining the process of award close out. These…
-
FY22 Fringe Rate Announcement
*Sent on behalf of the Office of Sponsored Programs & Research Grants and Contracts* Dear Colleagues, The FY22 federal and non-federal fringe rates have now been approved. The new rates are as follows: These fringe rates become effective on September 1, 2021. All proposals to federal sponsors (or for federal flow-through) should begin using the…
-
Research Administration Administrative Transitions
As we commence the school year, a number of leadership changes are underway. We have developed a framework for a smooth transition, ensuring continuous service to faculty. COI Come December, we will say goodbye to Assistant Vice President for Research Administration and Conflicts of Interest Director, Brenda Seiton, who is retiring after 25 years at…
-
ClinicalTrials.gov Pre-Notice & Notice of Noncompliance
The Food and Drug Administration (FDA) is taking action to ensure certain information in ClinicalTrials.gov is available to the public. On April 28, 2021, the FDA issued its first notice of non-compliance for failing to submit required results information. A Notice of Noncompliance indicates that the FDA has determined the Responsible Party (Principal Investigator) was…
-
ORA Spotlight: RGC Post Award Setup (PAS) Team
Did you know spending or billing cannot occur on your sponsored programs award without the Post Award Setup (PAS) team? The PAS team is the glue between OSP, RAS and RGC Operations. A small but powerful analysis team makes sure all sponsored awards are analyzed, reviewed, and ensures data integrity within the compass system. They…
-
Change in F&A Rate for Clinical Trials Effective 4/1/2021
The below message was sent on behalf of Dr. Robert Nobles, Vice President for Research Administration: March 12, 2021 Dear Colleagues, I am writing to share the outcome of an extensive review of our clinical trial definition and Facilities and Administrative Rate (F&A) rate. Over several months, we organized a working group that included faculty,…
-
Updated Guidance on Biosketch/Other Support Implementation
*Catch up on the Thursdays at Three (T@3) webinar addressing changes to the NIH Biosketch and Other Support here May 7, 2021 Dear Colleagues, We are writing to provide you the most up-to-date information on the transition to new formats for NIH Biosketches and Other Support pages. According to the most recent issue of the…